JP2010522218A5 - - Google Patents

Download PDF

Info

Publication number
JP2010522218A5
JP2010522218A5 JP2010500035A JP2010500035A JP2010522218A5 JP 2010522218 A5 JP2010522218 A5 JP 2010522218A5 JP 2010500035 A JP2010500035 A JP 2010500035A JP 2010500035 A JP2010500035 A JP 2010500035A JP 2010522218 A5 JP2010522218 A5 JP 2010522218A5
Authority
JP
Japan
Prior art keywords
dihydro
oxo
carbonyl
amino
cyclopropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010500035A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010522218A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2008/000561 external-priority patent/WO2008116304A1/en
Publication of JP2010522218A publication Critical patent/JP2010522218A/ja
Publication of JP2010522218A5 publication Critical patent/JP2010522218A5/ja
Pending legal-status Critical Current

Links

JP2010500035A 2007-03-26 2008-03-25 Ep4受容体アンタゴニストとしてのナフタレン及びキノリンスルホニル尿素誘導体 Pending JP2010522218A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92001807P 2007-03-26 2007-03-26
PCT/CA2008/000561 WO2008116304A1 (en) 2007-03-26 2008-03-25 Naphthalene and quinoline sulfonylurea derivatives as ep4 receptor antagonists

Publications (2)

Publication Number Publication Date
JP2010522218A JP2010522218A (ja) 2010-07-01
JP2010522218A5 true JP2010522218A5 (enExample) 2011-05-06

Family

ID=39787996

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010500035A Pending JP2010522218A (ja) 2007-03-26 2008-03-25 Ep4受容体アンタゴニストとしてのナフタレン及びキノリンスルホニル尿素誘導体

Country Status (7)

Country Link
US (1) US8003661B2 (enExample)
EP (1) EP2125724B1 (enExample)
JP (1) JP2010522218A (enExample)
CN (1) CN101636385B (enExample)
AU (1) AU2008232265B2 (enExample)
CA (1) CA2681146A1 (enExample)
WO (1) WO2008116304A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010034110A1 (en) * 2008-09-25 2010-04-01 Merck Frosst Canada Ltd. Beta-carboline sulphonylurea derivatives as ep4 receptor antagonists
EP2392323A4 (en) 2009-01-30 2012-09-26 Univ Kyoto INHIBITOR OF PROSTATE CANCER PROGRESSION AND METHOD OF INHIBITING PROGRESSION
WO2014143591A1 (en) 2013-03-12 2014-09-18 Allergan, Inc. Inhibition of neovascularization by simultaneous inhibition of prostanoid ip and ep4 receptors
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
TWI768043B (zh) 2017-05-18 2022-06-21 瑞士商愛杜西亞製藥有限公司 N-取代吲哚衍生物
US11839613B2 (en) 2017-05-18 2023-12-12 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives as PGE2 receptor modulators
PE20191814A1 (es) 2017-05-18 2019-12-27 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
TW201900179A (zh) 2017-05-18 2019-01-01 瑞士商愛杜西亞製藥有限公司 作為pge2受體調節劑之苯并呋喃及苯并噻吩衍生物
KR102612140B1 (ko) 2017-05-18 2023-12-08 이도르시아 파마슈티컬스 리미티드 피리미딘 유도체
US20230390303A1 (en) 2020-11-13 2023-12-07 Ono Pharmaceutical Co., Ltd. Cancer treatment by combination of ep4 antagonist and immune checkpoint inhibitor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9417532D0 (en) 1994-08-31 1994-10-19 Zeneca Ltd Aromatic compounds
GB9420557D0 (en) 1994-10-12 1994-11-30 Zeneca Ltd Aromatic compounds
US5834468A (en) 1995-07-07 1998-11-10 Zeneca Limited Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists
HN2001000224A (es) * 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
GB0031302D0 (en) * 2000-12-21 2001-01-31 Glaxo Group Ltd Napthalene derivatives
AU2003216581A1 (en) * 2002-04-12 2003-10-27 Pfizer Inc. Pyrazole compounds as anti-inflammatory and analgesic agents
WO2006122403A1 (en) * 2005-05-19 2006-11-23 Merck Frosst Canada Ltd. Quinoline derivatives as ep4 antagonists

Similar Documents

Publication Publication Date Title
JP2010522218A5 (enExample)
JP5941095B2 (ja) Atp結合カセット輸送体モジュレータ
JP2010525056A5 (enExample)
JP6021805B2 (ja) 腫瘍治療剤
TWI598098B (zh) 脂質異常症治療劑
JP2010503688A5 (enExample)
JP2016512825A5 (enExample)
JP2016507496A (ja) ブロモドメイン阻害剤としての新規複素環式化合物
JP2020512337A5 (enExample)
JP2011529049A5 (enExample)
JP2016534124A5 (enExample)
CN104023715B (zh) 激酶抑制剂的副作用降低剂
US20110065676A1 (en) Combination therapies comprising par1 antagonists with nar agonists
JP2011509301A5 (enExample)
JP2019505595A5 (enExample)
JP2011509302A5 (enExample)
JP2010516701A5 (enExample)
RU2018131775A (ru) 6-арил-4-морфолин-1-илпиридоны, пригодные для лечения рака или диабета
JP2016512227A5 (enExample)
US20250084091A1 (en) Inhibitors of sars-cov-2
JP2016525104A5 (enExample)
CN1516600A (zh) 用于治疗肿瘤疾病的联合药物
JP2019526546A5 (enExample)
EA019037B1 (ru) 5-[5-[2-[3,5-бис(трифторметил)фенил-2-метилпропаноилметиламино]-4-(4-фтор-2-метилфенил)]-2-пиридинил]-2-алкилпролинамиды в качестве антагонистов рецептора nk1
TW201202255A (en) Novel composition for the prevention and/or treatment of thromboembolism